Research Report: MRK

Analysis Date: 2025-12-16T15:07:29.709277 Trading Period: 2025-12-08 to 2025-12-19

Company Overview

Company: Merck & Co., Inc. Sector: Healthcare | Industry: Drug Manufacturers - General Current Price: $100.26 Market Cap: $250,427,752,448 Beta: 0.30 Avg Volume: 13,583,319 P/E Ratio: 13.26 Website: https://www.merck.com

Description: Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Trading Recommendation

Action: HOLD Confidence: 49.3/100 Position Size: 0.0% of portfolio

Rationale: Mixed signals (composite: 49.3/100, risk: LOW).

Key Strengths:

Screening Status

Passed Filters: ✓ Yes Notes: Passed all screening filters

Quantitative Analysis

Composite Score: 2.80/5.0 Percentile Rank: 50%

Factor Scores:

Technical Analysis

Setup Score: 2/8 Setup Notes: In uptrend; Chart patterns: Recent Breakout

Price Levels:

Momentum & Volume:

Chart Patterns:

Technical Risk Factors:

Risk Assessment

Risk Level: LOW Confidence: 70.0/100 Total Red Flags: 1 Earnings Risk: No

Market Red Flags:


This report is generated by PM automated research system. Always perform your own due diligence before trading.